GEMINA LABS LTD Total Liabilities
GEMINA LABS LTD total liabilities. Based on the latest financial reports, GEMINA LABS LTD (8I7) has total liabilities worth €6.25 Million EUR (≈ $7.31 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of GEMINA LABS LTD to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GEMINA LABS LTD (2022–2025)
Total liabilities of GEMINA LABS LTD from 2022 to 2025. This chart illustrates how GEMINA LABS LTD's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of GEMINA LABS LTD to see how much of total assets are deployed in long-term investments.
GEMINA LABS LTD Competitors by Total Liabilities
The table below lists competitors of GEMINA LABS LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tanah Laut Tbk
JK:INDX
|
Indonesia | Rp21.99 Billion |
|
Brickability Group Plc
LSE:BRCK
|
UK | GBX254.22 Million |
|
Ranchero Gold Corp
V:RNCH
|
Canada | CA$319.68K |
|
CanadaBis Capital Inc
V:CANB
|
Canada | CA$16.64 Million |
|
Sabio Holdings Inc
V:SBIO
|
Canada | CA$23.08 Million |
|
Ngenic AB
ST:NGENIC
|
Sweden | Skr65.29 Million |
|
Edison Lithium Corp
V:EDDY
|
Canada | CA$63.28K |
|
CBEYOND
F:C5B
|
Germany | €400.03K |
Liability Composition Analysis (2022–2025)
This chart breaks down GEMINA LABS LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GEMINA LABS LTD assets under control.
Liquidity & Leverage Metrics
GEMINA LABS LTD Total Liabilities Ratios Explained
GEMINA LABS LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GEMINA LABS LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GEMINA LABS LTD (2022–2025)
The table below shows the annual total liabilities of GEMINA LABS LTD from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | €5.87 Million ≈ $6.87 Million |
+93.11% |
| 2024-01-31 | €3.04 Million ≈ $3.56 Million |
+56.23% |
| 2023-01-31 | €1.95 Million ≈ $2.28 Million |
+309.06% |
| 2022-01-31 | €475.92K ≈ $556.40K |
-- |
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more